Analytical Data
-
基因名
F10
- Application
-
别名
F10；C10orf4；Protein FRA10AC1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P00742
-
表达区间
41-488aa
-
氨基酸序列
ANSFLEEMKKGHLERECMEETCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKNCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERRKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK
-
分子量
57.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The F10 protein, known as factor X or Stuart-Prower factor, plays a critical role in the coagulation cascade, functioning as a key prothrombinase that converts prothrombin to thrombin, ultimately leading to fibrin formation in blood clotting. Research on F10 recombinant protein has gained prominence due to its potential applications in hemophilia treatment, anticoagulation therapy, and enhancing our understanding of hemostasis mechanisms. Recombinant F10 can be engineered to improve its therapeutic efficacy, reduce immunogenicity, and provide a more stable production platform compared to traditional methods. The advancements in biotechnology, particularly in the fields of genetic engineering and protein expression systems, have paved the way for the development of highly purified, functional F10 proteins. Coupled with the growing interest in personalized medicine and target-specific therapies, the study of F10 recombinant proteins holds promise for innovative treatment strategies in coagulation disorders, contributing to improved patient outcomes. As the understanding of the blood coagulation pathway deepens, the targeted manipulation of F10 and its interactions with other coagulation factors presents exciting opportunities for research and therapeutic development in the field of hematology.
